Objective:

To evaluate the impact of achieving serum urate targets on cardiovascular risk in patients with gout.

Approach:

Key Findings:

• Fewer than one-third of patients achieved recommended serum urate targets within 12 months.
• Achieving serum urate levels <6 mg/dL was associated with a 9% relative risk reduction for major adverse cardiovascular events (MACE).
• Patients with high or very high baseline cardiovascular risk showed the strongest association.
• Achieving serum urate levels <5 mg/dL was linked to a 23% relative risk reduction.
• 5-year cardiovascular event-free survival was 89% in the treat-to-target group vs. 88% in the non-treat-to-target group.

Interpretation:

The study suggests that a treat-to-target approach in managing serum urate levels in gout patients may significantly reduce cardiovascular risks, particularly in those with higher baseline risks.

Limitations:

• Residual confounding cannot be fully excluded despite extensive adjustments.
• Potential surveillance bias due to inclusion of patients with prior cardiovascular events.
• Exposure misclassification possible as serum urate levels were not measured in all patients during the first 12 months.
• Incomplete capture of gout flares in routine care data.

Conclusion:

The findings support the importance of a treat-to-target approach in urate-lowering therapy for gout, given its potential cardiovascular benefits.

Sources:

• JAMA Internal Medicine
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.